ABSTRACT -Anaemia is a significant prognostic factor in cancer patients receiving anticancer drugs such as methotrexate (MTX). This study focuses on the effects of toxicological changes on the hematopoietic systems in male and female Wistar Hannover rats when MTX is orally administered at a dose of 0, 0.05, 0.15, or 0.45 mg/(kg·day) for a period of 28 days. Both male and female rats receiving 0.45 mg/kg MTX showed a decrease in the haemoglobin concentration (Hb), haematocrit, and erythrocyte count. Female rats showed a decrease in mean corpuscular volume (MCV) and an increase in cell mean Hb (CHCM) in total erythrocytes, including the mature erythrocytes. These results indicate that MTX causes the production of small, mature erythrocytes that contain a high concentration of Hb. MTX reduced the number of peripheral reticulocytes but produced the cells with a large size and a high concentration of Hb, as demonstrated by the reticulocyte MCV and CHCM as well as the content of haemoglobin per reticulocyte (CHr). Consistent with these findings, bone marrow haematopoiesis was impaired by MTX, as there was a reduction in erythroid count in rats of both sexes. The number of cells of the myeloid lineage reduced in female rats, followed by a reduction in the total leukocyte and neutrophil counts in peripheral blood. Thrombocytopenia was detected in a small population of rats. These results indicate that MTX induces hyperchromic microcytic anaemia and pancytopenia, and the use of MCV and CHCM in mature erythrocytes and reticulocytes, along with the CHr, gives a better understanding of the development and nature of anaemia.
INTRODUCTION
Methotrexate (MTX) is a competitive inhibitor of dihydrofolate reductase (DHFR), which drives the NADPH-dependent conversion of 7,8-dihydrofolate to 5, 6, 7, ) (Jolivet et al., 1983; Schornagel and McVie, 1983) . FH 4 is a precursor of the active folate cofactor forms required for the synthesis of thymidylate, purine, methionine, and serine. Cells exposed to MTX are presumed to die due to either depletion of the reduced folate or decrease in DNA and RNA synthesis that leads to inhibition of cell growth. MTX has been widely used as an anticancer drug (Jolivet et al., 1983; Schornagel and McVie, 1983) . Moreover, it has been useful in the treatment of rheumatoid arthritis (Cutolo et al., 2001) . The anti-inflammatory effects exerted by MTX are related to the increase in extracellular adenosine and its interaction with specific cell receptors; MTX inhibits AMP deaminase and adenosine deaminase (ADA) via a relative increase in the levels of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) (Cutolo et al., 2001) . The major side effects of MTX treatment are the development of drug-resistant tumour cells (Fotoohi et al., 2004; Sorich et al., 2008) , gastrointestinal toxicity (May et al., 1995; Vardi et al., 2008) , bone marrow toxicity (Ermens et al., 1989; May et al., 1995; James et al., 2000; Belur et al., 2005) , and pancytopenia (Chan et al., 2004; Cohen et al., 2005; McEwen et al., 2007) Anaemia is one of the most significant prognostic factors of MTX toxicity among patients with cancer or rheumatoid arthritis during the treatment period (Han et al., 2007; Dubsky et al., 2008) . However, haematological changes along with bone marrow cytology have not been documented in rats, and limited data is available from studies using unilaterally nephrectomised rats treated with MTX that show the progression of severe anaemia in the absence of reticulocyte adaptation (Murakami et al., 1998) . In this study, we determined the haematological and bone marrow toxicity in Wistar Hannover rats following a 4-week course of repeated oral administration of MTX. Moreover, we assessed the pathological effects of MTX on the immune system to better understand inducible pancytopenia.
MATERIALS AND METHODS

Animal husbandry and experimental design
Six-week-old male and female Wistar Hannover SPF (BrlHan:WIST@Jcl [GALAS]) rats were obtained from CLEA Japan, Inc. (Shizuoka, Japan) (males, n = 48; females, n = 50). MTX administered to healthy animals was initiated when the rats were 7-weeks-old. Rats were housed in cages maintained under suitable temperature (23°C ± 2°C), humidity (55% ± 15%), ventilation (continuous circulation of fresh air), and illumination conditions (a 12-hr light/dark cycle). Rats were housed individually, and the animals had ad libitum access to a pellet diet (Oriental MF; Oriental Yeast Co., Tokyo, Japan) and tap water. Rats were carefully observed every day during the study. All the animals were handled in accordance with the Guidelines for Animal Experimentation issued by the Japanese Association for Laboratory Animal Science (JALAS, 1987) . The current study was conducted in accordance with the Code of Ethics for Animal Experimentation of the Institute of Environmental Toxicology.
Rats were divided into four groups: each group consisted of 10 males and 10 females and each animal was given MTX by gavage at a dose of 0, 0.05, 0.15, or 0.45 mg/(kg·day) for 4 weeks (28 days). Briefly, 5 mg/ml of MTX was dissolved in 0.02 mol/l of sodium hydrate solution and then diluted to 0.01, 0.03, or 0.09 mg/ml with sodium hydrate and distilled water for injecting (Ohtsuka Pharmaceutical Co., Tokyo, Japan) doses of 0.05, 0.15, or 0.45 mg/kg. The dose volume was 5 ml/kg. The doses were selected on the basis of a previously reported 4-week repeated-dose oral toxicity study of unilaterally nephrectomised Sprague-Dawley (SD) rats that received MTX orally at a doses of 0.06, 0.2, or 0.6 mg/ (kg·day) (Murakami et al., 1998) . Stability of MTX at 0.004 and 0.12 mg/ml was ensured for the study: MTX was sealed and stored in cold and dark conditions for 7 days and then exposed to ambient air for 4 hr (over 99% of initial values at each dose level). MTX was prepared weekly and used for administration within the defined period. Appropriate concentration was ensured at each dose level collected in the first and last preparations (101% to 104% of nominal dose). Concentration of MTX was determined using high-performance liquid chromatography (HPLC) with UV detection (JASCO Co., Tokyo, Japan). Each sample (10 μl) was injected into a TSK gel ODS-80Ts (Tosoh Co., Tokyo, Japan) maintained at 45°C, and the peaks obtained were comparable with those of the internal control (folic acid). The HPLC system was operated in an isocratic mode with acetonitrile-sodium dihydrogen phosphate/citric buffer (pH 6.0) at a flow rate of 1 ml/min and with UV detection at 302 nm. The detection limit was 0.0005 mg/ml.
Haematology
Following treatment with MTX for 4 weeks, blood samples were collected from the posterior vena cava of each of the animals under ether anaesthesia after overnight fasting. These samples were then subjected to haematological and blood chemical tests. Haematological parameters including haematocrit (Ht), haemoglobin concentration (Hb), erythrocyte count (RBC), total erythrocyte mean corpuscular volume (MCVt), mature erythrocyte MCV (MCVm), reticulocyte MCV (MCVr), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), total red cell mean Hb content (CHCMt), mature erythrocyte CHCM (CHCMm), reticulocyte CHCM (CHCMr), content of haemoglobin per reticulocyte (CHr), red cell distribution width (RDW), haemoglobin distribution width (HDW), reticulocyte count (Retics), platelet count (PLT), mean platelet volume (MPV), plateletcrit (PCT), mean platelet component (MPC), platelet component distribution width (PCDW), mean platelet mass (MPM), platelet mass distribution width (PMDW), total leukocyte count (WBC), and differential leukocyte count (lymphocyte, neutrophil, monocyte, eosinophil, and basophil) were tested with the ADVIA120 Hematology System (Siemens Healthcare Diagnostics). Smears of bone marrow from the femur were prepared and stained by the May-Grünwald and Giemsa method for differential count (of immature erythroblast [proerythroblast and basophilic erythroblast], erythroblast, myeloblast, promyelocyte, myelocyte, metamyelocyte, neutrophil, eosinophil, basophil, myeloid/ erythroid ratio [M/E ratio], lymphocyte, monocyte, plasma cell, megakaryocyte, mast cell, reticulum cell, macrophage, mitotic cell, and unclassified cell). Total cell, erythroid/lymphocyte, and myeloid cells in the bone marrow were counted with ADVIA 120 Hematology System.
Pathology
Samples of the thymus, spleen, and bone marrow (femur, sternum, and vertebra) were fixed in 10% buffered formalin solution, and tissue sections of these samples were stained with haematoxylin and eosin for histopathological examination.
Statistical analysis
Data are represented by the mean and standard deviation (SD). Dunnett's multiple comparison test was used to determine the significance of differences in the results between the treated and control groups. A p value below 0.05 was considered to be significant.
RESULTS
Comparison of haematological parameters including reticulocyte parameters with erythroid cells in bone marrow cytology
Haematolological parameters
In the 0.45 mg/(kg·day) group, one male died at week 3 and one female was sacrificed due to moribundity at week 4. These were plausibly caused by severe anaemia. After 4 weeks of treatment, rats of both sexes showed a statistically significant decrease in Hb, Ht, and RBC (Table 1) , whereas female rats showed a statistically significant decrease in MCVt and MCVm (Figs. 1A, 1B), indicating 18.8 ± 0.6 18.6 ± 0.6 19.0 ± 0.5 18.4 ± 0.6 MCHC (g/dl)
35.2 ± 0.5 35.0 ± 0.7 35.2 ± 0.7 36.0 ± 0.7* RDW (%) 10.9 ± 0.6 10.7 ± 0.5 10.9 ± 0.5 11.2 ± 0.9 HDW (g/dl)
2.21 ± 0.13 2.16 ± 0.14 2.20 ± 0.13 2.38 ± 0.13* PLT (10 3 /μl) 1260 ± 135 1201 ± 141 1282 ± 157 1784 ± 1007 MPV (fl) 8.4 ± 0.4 8.6 ± 0.6 8.6 ± 0.4 8.8 ± 0.5 PCT (%)
1.06 ± 0.13 1.04 ± 0.13 1.10 ± 0.14 1.55 ± 0.87
18.6 ± 0.3 18.8 ± 0.5 18.3 ± 0.4 17.9 ± 0.8* PCDW (g/dl)
6.9 ± 0.3 7.0 ± 0.3 6.9 ± 0.2 6.6 ± 0.3 MPM (pg) (2) small mature erythrocytes with a high concentration of haemoglobin were distributed in the peripheral blood of rats treated with MTX.
Erythroid cells in bone marrow cytology
Bone marrow haematopoiesis was impaired by MTX, due to the decrease (statistically significant) in the total nucleated erythroid count in the bone marrow of both male and female rats that received 0.45 mg/(kg·day) MTX (Figs. 2A, 2B ). Although automated cell counts by the ADVIA120 did not distinguish erythroid cells from lymphocytes, the combined counting was correlated with manual counts of immature erythroblasts and erythroblasts in bone marrow smears (Table 2) . A statistically significant increase in M/E ratio was observed in the rats of both sexes as well. Importantly, the tendency of mitotic cell counts to decrease in rats of both sexes plausibly indicated a reduction in cell proliferation activity in the Fig. 2 . Bone marrow analysis by ADVIA120. Total cell count (A), combined erythroid cell and lymphocyte counts (B), and myeloid cell count (C) were analyzed in bone marrow samples by ADVIA120. ADVIA120 did not distinguish erythroid cells from lymphocyte, but the combined data were consistent with those obtained from bone marrow smears, i.e. immature erythroblast/erythroblast counts and lymphocyte count (see Table 2 ). 
Reticulocyte parameters
Consistent with the reduction in bone marrow erythroid cells, peripheral reticulocytes were prominently repressed, especially in female rats (Fig. 3A) . These reticulocytes were, however, larger than those of the controls. Moreover, the concentration of haemoglobin in these reticulocytes was higher than that of the reticulocytes in the control group, as demonstrated by the MCVr, CHCMr, and CHr (Figs. 3B-3D) . A characteristic increase in distribution width was observed in female rats for cell haemoglobin concentration (HDW, anisochromia) ( Table 1) .
Platelet parameters
In the 0.45 mg/(kg·day) group, rats of both sexes had a tendency to increase in PLT and PCT (equivalent to haematocrit of erythrocyte) (Table 1) . When reviewed individual data of PLT and PCT, however, two prominent populations were detected: one (four males and six females) was clearly higher than the upper limit of the control and others (one male and two females) were lower than the lower limit of the control (Fig. 4) . The two females showed extremely low levels of PLT and PCT. The data indicated that a small population of rats showed thrombocytopenia, while others showed thrombocytosis. Platelets had normal size and mass as shown by MPV, MPM, and PMDW but the cells were activated as demon- strated by MPC and/or PCDW (indicators of platelet activation) (Nadar et al., 2004; Ashman et al., 2003; Bae et al., 2003) .
Comparison of peripheral leukocytes with myeloid cells in bone marrow cytology
Reduction in peripheral leukocytes such as lymphocytes, neutrophils, and monocytes was evident in female rats (Table 1) . Consistent with a decrease in peripheral neutrophil count, there was a significant decrease in the myeloblast, myelocyte, and metamyelocyte counts; the promyelocyte and neutrophil counts in the bone marrow from female rats showed a tendency to decrease (Table 2) . A tendency of myeloid cells to decrease was confirmed by the automatic cell count by ADVIA120 (Fig. 2C) . In contrast, the bone marrow smears showed a significant increase in the eosinophil, mast cell, and reticulum cell counts in female rats and a tendency for increase in mast cells in male rats (Table 2 ). These findings were consistent with a previous report showing that following hypocellularity owing to erythroid and myeloid lineages (except eosinophil), other cell elements such as eosinophil and reticuloendothelial cell were only formed after MTX treatment in rats (Ferguson et al., 1975) . Other changes were minor and/or nonspecific.
Histopathology
Consistent with the impairment of haematopoiesis demonstrated by haematological alterations, decreased haematopoiesis in the bone marrow (femur, sternum, and Vol. 37 No. 5 vertebra) was pathologically observed in 6 of the 10 male rats and in all female rats that received 0.45 mg/(kg·day) MTX (Table 3 ). As to lymphoid tissues, histiocytic hyperplasia in the spleen was observed in 4 of the 10 male rats and 7 of the 10 female rats at the high dose level; this might be associated with a reduction of the B-cell population caused by MTX treatment, as previously reported (Zandvoort et al., 2001) . Cortical atrophy in the thymus was noted in 4 of the 10 female rats that received a high dose of MTX. A similar thymic change was observed in 4 of the 10 males that received 0.45 mg/(kg·day) MTX and in 1 of the 10 males that received 0.15 mg/(kg·day) MTX.
DISCUSSION
In the present study, we found that forced oral administration of MTX induced hyperchromic microcytic anaemia and leukocytopenia as well as the impairment of bone marrow haematopoiesis in Wistar Hannover rats. As female rats were more sensitive to MTX-induced anaemic changes than male rats, leukocytopenia was observed only in female rats. These changes were consistent with the data obtained from patients suffering from anaemia and pancytopenia and who were taking MTX during therapy (Chan et al., 2004; Cohen et al., 2005; McEwen et al., 2007) . Interestingly, MTX caused an inverse effect on platelet, i.e. thrombocytopenia and thrombocytosis, and severe thrombocytopenia was observed in a small population of female rats. An earlier clinical study demonstrated that thrombocytosis was followed by thrombocytopenia as a "rebound" phenomenon in patients taking MTX (Ogston et al., 1968) . Moreover, the results were also consistent with a previous report using MTX-treated SD rats following unilateral nephrectomy or a sham operation (Murakami et al., 1998) . Bone marrow cytology has not been included in the study of MTX-treated SD rats (Murakami et al., 1998) . We showed that MTX impaired haematopoiesis not only in erythroid linage but also in myeloid linage of the bone marrow. An alteration in myeloid linage was clearly related to neutropenia observed in female rats that were treated at 0.45 mg/(kg·day). Our data support the notion that MTX is a potential inducer of pancytopenia, although the presence of inducible pancytopenia in patients while receiving MTX is controversial (Yazici, 2006) . It should be emphasized, however, that severe thrombocytopenia is restricted under the present study condition.
The present study clearly showed that CHCMt, CHCMm, CHCMr, and/or CHr increased due to MTX administration when compared to that of the control groups. This indicates that MTX enhances haemoglobin synthesis in mature erythrocytes and reticulocytes, both of which were reduced in the peripheral blood. CHCM represents the mean Hb measured directly from individual red cells. In contrast to MCHC, which is a derived value, CHCM is not affected by error in the measurement of Hb and Ht (Saw and Tham, 1988) . CHr measurement is a direct assessment of the incorporation of Fe into erythrocyte haemoglobin, and it is free from the biological variability that affects Fe, transferrin measurements, and transferrin saturation (Goodnough et al., 2000; Thomas and Thomas, 2002; Ullrich et al., 2005) . Our data suggests that CHCM and CHr are critical parameters for characterizing anaemia, and this is supported by our previous study (Kojima et al., 2009 ) and other study (Honda et al., 2008) . Classically, MTX efficacy depends on its inhibition of DHFR, resulting in depletion of intracellular reduced folates that are crucial for biosynthesis of purines and thymidilic acid, the precursors of DNA (Jolivet et al., 1983; Schornagel and McVie, 1983; Blakley, 1995) . The deceleration of DNA synthesis with normal cytoplasmic RNA synthesis leads, over several divisions, to synchrony between the rates of cytoplasmic and nuclear maturation. The concept is good agreement with our data that MTX reduced mitotic figures in the bone marrow smears. This unbalanced growth affects all proliferating cells, but is most readily observed in bone marrow cells, which morphologically appear to be megaloblastic (Salah et al., 1999) . Megaloblastic anaemia has been reported in patients receiving MTX (Iwama et al., 1992; Salah et al., 1999) , who have large-sized erythrocytes and reticulocytes (Clarkson and Moore, 1976) . In the present experiments, we found that MTX reduced MCVm and enhanced MCVr. Arguments can be posed to explain the slow onset of macrocytosis in patients with megaloblastic anaemia (Clarkson and Moore, 1976) . In fact, adult mice fed folate-free diet develop macrocytosis with anaemia even after 5 weeks of treatment (Koury et al., 2000) . In its megaloblastic erythropoiesis model, the colony forming units-erythroid (CFU-E) and proerythroblast population predominate because apoptosis of basophilic and polychromatophilic erythroblasts in response to DNA damage greatly reduced their numbers, leading to a decrease in the reticulocyte numbers, while the remaining erythroblasts that completely differentiate produce large-sized reticulocytes.
Our data showed that MTX induces pancytopenia in female rats, and these changes could be related to not only the reduction in cells of the myeloid linage in the bone marrow but also atrophic change in the thymus and hyperplasia of histiocytes in the spleen. These results were consistent with those of some studies using rats treated with MTX. Indeed, a single intravenous injection of MTX reduces the pro/pre B-cell population in spleen tissue, where a reduction of CD90 + cells in the lymphocyte corona is observed (Zandvoort et al., 2001) . Thymic atrophy has been reported in rats treated with 0.2 and 0.6 mg/ (kg·day) MTX for 28 days (Murakami et al., 1998) . MTX is a potential inducer of apoptosis in isolated neutrophils and lymphocytes (Cetiner et al., 2005) . Studies show that induction of anti-inflammatory autocoid adenosine and its binding to type A2 and A3 receptors by MTX subsequently increases cyclic adenosine monophosphate that is crucial for the immunosuppressive and anti-inflammatory effects, which are thought to be useful in patients with rheumatoid arthritis (Cutolo et al., 2001) . These changes are mediated by inhibiting AMP deaminase and ADA. ADA is a critical mediator in thymus development, as ADA-deficient mice show increased thymic apoptosis and have defective T-cell receptor signalling (Thompson et al., 2000; Apasov et al., 2001; Van De Wiele et al., 2002) . These mice also showed pulp hypoplasia with relative red pulp expansion in the spleen and a low level of circulating B220 + IgM + B cells, which are normalized by gene therapy with ADA (Mortellaro et al., 2006) . Although MTX increases the splenic content of AICAR, which is a critical mediator of adenosine release, how MTX impairs adenosine and ADA signalling in the thymus and the spleen is not completely understood.
Patients develop pancytopenia as a fatal complication with MTX with age and multiple other medications (Yazici, 2006) . Individual clinical data show that female patients are more likely to be affected than male patients (Chan et al., 2004; Lim et al., 2005) , however those should be interpreted carefully as woman is generally liable to rheumatoid arthritis. Nevertheless, an earlier assessment would be important for therapeutic indications for which patient populations are at higher risk of pancytopenia, e.g. poor nutrition, hypoalbuminaemia, and decreased renal clearance, resulting in increased blood levels of MTX (Lim et al., 2005) . In our study, there were no significant changes in body weight, food consumption, and selected blood biochemical parameters such as albumin, glucose, total cholesterol, and triglyceride in treated animals of either sex (data not shown), and the data suggest that nutritional conditions and albumin level does not contribute to sex difference in sensitivity to MTX-inducing pancytopenia. Renal clearance of MTX needs to be further examined, as a renal basolateral transporter, mouse organic anion transporter 3 (OAT3) regulated MTX clearance in a gender-dependent manner (VanWert and Sweet, 2008 ) and a functional heterogeneity was identified in human OAT3 variants (Erdman et al., 2006) .
The present results indicate that MTX induces hyperchromic microcystic anaemia in rats of both sexes, and causes pancytopenia especially in female rats. These results were based on bone marrow, spleen, and thymus toxicities; female rats were likely to be more sensitive than male rats. MTX reduced the size of mature erythrocytes, whereas it enhanced the size of reticulocytes. However, the decrease in the erythrocyte and reticulocyte counts was significant. Recent evidence suggests that MTX-induced tissue damage is mediated by inhibition of DHFR, induction of adenosine, and/or generation of oxidative stress. Therefore, further studies are required to understand each of the mechanisms by which MTX affects the integrity of erythroid, myeloid, and lymphoid lineages. We also found that the use of MCV and CHCM as well as CHr as parameters for measuring mature erythrocytes and reticulocytes allows better understanding of the development and nature of anaemia.
